[18f]ceto
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2019 (NCT05361083)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06616142 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | University of Groningen |
| NCT05472493 | Phase 2 | Jan 1, 2023 | University of Calgary |
| NCT04529018 | N/A | Aug 3, 2020 | University of Cambridge |
| NCT05361083 | Early Phase 1 (Phase 1) | Sep 1, 2019 | Medical Research Council, Uppsala University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medical Research Council | Government | 1 | 0 | 1 | 2019 |
| University of Calgary | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Cambridge | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Uppsala University | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1